208 related articles for article (PubMed ID: 37218658)
1. Physician Perspectives on the Food and Drug Administration's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease.
Dhruva SS; Kesselheim AS; Woloshin S; Ji RZ; Lu Z; Darrow JJ; Redberg RF
Clin Pharmacol Ther; 2023 Sep; 114(3):614-617. PubMed ID: 37218658
[TBL] [Abstract][Full Text] [Related]
2. Aducanumab for Alzheimer's disease: A regulatory perspective.
Nisticò R; Borg JJ
Pharmacol Res; 2021 Sep; 171():105754. PubMed ID: 34217830
[TBL] [Abstract][Full Text] [Related]
3. Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey.
DiStefano MJ; Alexander GC; Polsky D; Anderson GF
J Am Geriatr Soc; 2022 Jun; 70(6):1685-1694. PubMed ID: 35129210
[TBL] [Abstract][Full Text] [Related]
4. Making the Case for Accelerated Withdrawal of Aducanumab.
Whitehouse P; Gandy S; Saini V; George DR; Larson EB; Alexander GC; Avorn J; Brownlee S; Camp C; Chertkow H; Fugh-Berman A; Howard R; Kesselheim A; Langa KM; Perry G; Richard E; Schneider L
J Alzheimers Dis; 2022; 87(3):1003-1007. PubMed ID: 35404287
[TBL] [Abstract][Full Text] [Related]
5. Ignoring the Experts: Implications of the FDA's Aduhelm Approval.
Maulden A
Am J Law Med; 2022 Mar; 48(1):108-133. PubMed ID: 35815585
[TBL] [Abstract][Full Text] [Related]
6. Can we learn lessons from the FDA's approval of aducanumab?
Liu KY; Howard R
Nat Rev Neurol; 2021 Nov; 17(11):715-722. PubMed ID: 34535787
[TBL] [Abstract][Full Text] [Related]
7. Accelerated Approval of Aducanumab: Where Do We Stand Now?
Barenholtz Levy H
Ann Pharmacother; 2022 Jun; 56(6):736-739. PubMed ID: 34595939
[TBL] [Abstract][Full Text] [Related]
8. Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.
Vaz M; Silva V; Monteiro C; Silvestre S
Clin Interv Aging; 2022; 17():797-810. PubMed ID: 35611326
[TBL] [Abstract][Full Text] [Related]
9. An insider's perspective on FDA approval of aducanumab.
Wang Y
Alzheimers Dement (N Y); 2023; 9(2):e12382. PubMed ID: 37215506
[TBL] [Abstract][Full Text] [Related]
10. Controversial Approval of New Drug to Treat Alzheimer's Disease.
Aschenbrenner DS
Am J Nurs; 2021 Oct; 121(10):22-23. PubMed ID: 34554982
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer's and Aducanumab: Unjust Profits and False Hopes.
Fleck LM
Hastings Cent Rep; 2021 Jul; 51(4):9-11. PubMed ID: 34156732
[TBL] [Abstract][Full Text] [Related]
12. Extending the US Food and Drug Administration's Postmarket Authorities.
Fernandez Lynch H; Sachs RE; Lee S; Herder M; Ross JS; Ramachandran R
JAMA Health Forum; 2023 Jun; 4(6):e231313. PubMed ID: 37294583
[TBL] [Abstract][Full Text] [Related]
13. [Aducanumab and Alzheimer's disease: a critical reflection.].
Vanacore N; Blasimme A; Canevelli M
Recenti Prog Med; 2021; 112(7):495-498. PubMed ID: 34263875
[TBL] [Abstract][Full Text] [Related]
14. Lessons Learned from Approval of Aducanumab for Alzheimer's Disease.
Heidebrink JL; Paulson HL
Annu Rev Med; 2024 Jan; 75():99-111. PubMed ID: 38285515
[TBL] [Abstract][Full Text] [Related]
15. Physicians' Trust in the FDA's Use of Product-Specific Pathways for Generic Drug Approval.
Kesselheim AS; Eddings W; Raj T; Campbell EG; Franklin JM; Ross KM; Fulchino LA; Avorn J; Gagne JJ
PLoS One; 2016; 11(10):e0163339. PubMed ID: 27768700
[TBL] [Abstract][Full Text] [Related]
16. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease.
Mukhopadhyay S; Banerjee D
J Alzheimers Dis; 2021; 83(4):1537-1552. PubMed ID: 34366359
[TBL] [Abstract][Full Text] [Related]
17. Improving Food and Drug Administration-Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated Approval.
Neumann PJ; Crummer E; Chambers JD; Tunis SR
Milbank Q; 2023 Dec; 101(4):1047-1075. PubMed ID: 37644739
[TBL] [Abstract][Full Text] [Related]
18. Physicians' Perspectives On FDA Regulation Of Drugs And Medical Devices: A National Survey.
Dhruva SS; Kesselheim AS; Woloshin S; Ji RZ; Lu Z; Darrow JJ; Redberg RF
Health Aff (Millwood); 2024 Jan; 43(1):27-35. PubMed ID: 38190596
[TBL] [Abstract][Full Text] [Related]
19. Analysis of FDA's Accelerated Approval Program Performance December 1992-December 2021.
Beakes-Read G; Neisser M; Frey P; Guarducci M
Ther Innov Regul Sci; 2022 Sep; 56(5):698-703. PubMed ID: 35900722
[TBL] [Abstract][Full Text] [Related]
20. How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyond.
Lythgoe MP; Prasad V
Eur J Cancer; 2021 Nov; 157():68-70. PubMed ID: 34487987
[No Abstract] [Full Text] [Related]
[Next] [New Search]
